An expert panel suggests setting limits on recombinant human factor VII (rFVIIa, NovoSeven®) therapy for bleeding because of concerns about its safety, effectiveness, and cost.
You are here
P&T® Journal contents for November 2005
Consensus Recommendations for the Off-Label Use of Recombinant Human Factor VIIa (NovoSeven®) Therapy
Ms. Pauli reflects on a paradigm shift that is taking place in drug development and patient care: from global treatment modalities to more individualized therapeutics based on genomic data.
The authors offer a preview of what will take place for “dual eligibles,” whose costs for prescription drugs were covered by both Medicaid and Medicare, as they are transferred from Medicaid to the new Medicare drug plans in 2006.
Dr. Goldenberg reviews exemestane (Aromasin®) for treating estrogen receptor–positive breast cancer; a vaccine (Proquad®) for protection against measles, mumps, rubella, and chickenpox in children; and a vaccine (Fluarix™) for immunization against influenza virus types A and B in adults.
Therapies for migraine, multiple sclerosis, Parkinson’s disease, diabetic peripheral neuropathy, agitation, Alzheimer’s disease, and other disorders are presented.